PLXND1

Across TCGA pan-cancer cohorts, PLXND1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PLXND1 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PLXND1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLXND1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

SCLC, MESO, and READ are the cancer types where PLXND1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	24	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
READ	OS	Median	IV	0.111	0.893	<.001	15	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
LIHC	OS	Median	All	0.476	0.788	.014	12	view →
BLCA	DFS	Median	All	0.154	0.497	.044	6	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	4	view →
KIRC	OS	Median	All	0.253	0.631	.026	2	view →
STAD	DFS	Median	III,IV	0.694	0.330	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PLXND1–SCLC (OS)

Open the SCLC breakdown →